PURPOSE: This study was conducted to study the influence of protein structure on the immunogenicity in wild-type and immune tolerant mice of well-characterized degradation products of recombinant human interferon alpha2b (rhIFNalpha2b). METHODS: RhIFNalpha2b was degraded by metal-catalyzed oxidation (M), cross-linking with glutaraldehyde (G), oxidation with hydrogen peroxide (H), and incubation in a boiling water bath (B). The products were characterized with UV absorption, circular dichroism and fluorescence spectroscopy, gel permeation chromatography, reverse-phase high-pressure liquid chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, Western blotting, and mass spectrometry. The immunogenicity of the products was evaluated in wild-type mice and in transgenic mice immune tolerant for hIFNalpha2. Serum antibodies were detected by enzyme-linked immunosorbent assay or surface plasmon resonance. RESULTS: M-rhIFNalpha2b contained covalently aggregated rhIFNalpha2b with three methionines partly oxidized to methionine sulfoxides. G-rhIFNalpha2b contained covalent aggregates and did not show changes in secondary structure. H-rhIFNalpha2b was only chemically changed with four partly oxidized methionines. B-rhIFNalpha2b was largely unfolded and heavily aggregated. Nontreated (N) rhIFNalpha2b was immunogenic in the wild-type mice but not in the transgenic mice, showing that the latter were immune tolerant for rhIFNalpha2b. The anti-rhIFNalpha2b antibody levels in the wild-type mice depended on the degradation product: M-rhIFNalpha2b > H-rhIFNalpha2b approximately N-rhIFNalpha2b >> B-rhIFNalpha2b; G-rhIFNalpha2b did not induce anti-rhIFNalpha2b antibodies. In the transgenic mice, only M-rhIFNalpha2b could break the immune tolerance. CONCLUSIONS: RhIFNalpha2b immunogenicity is related to its structural integrity. Moreover, the immunogenicity of aggregated rhIFNalpha2b depends on the structure and orientation of the constituent protein molecules and/or on the aggregate size.
PURPOSE: This study was conducted to study the influence of protein structure on the immunogenicity in wild-type and immune tolerant mice of well-characterized degradation products of recombinant humaninterferon alpha2b (rhIFNalpha2b). METHODS: RhIFNalpha2b was degraded by metal-catalyzed oxidation (M), cross-linking with glutaraldehyde (G), oxidation with hydrogen peroxide (H), and incubation in a boiling water bath (B). The products were characterized with UV absorption, circular dichroism and fluorescence spectroscopy, gel permeation chromatography, reverse-phase high-pressure liquid chromatography, sodium dodecyl sulfatepolyacrylamide gel electrophoresis, Western blotting, and mass spectrometry. The immunogenicity of the products was evaluated in wild-type mice and in transgenic mice immune tolerant for hIFNalpha2. Serum antibodies were detected by enzyme-linked immunosorbent assay or surface plasmon resonance. RESULTS: M-rhIFNalpha2b contained covalently aggregated rhIFNalpha2b with three methionines partly oxidized to methionine sulfoxides. G-rhIFNalpha2b contained covalent aggregates and did not show changes in secondary structure. H-rhIFNalpha2b was only chemically changed with four partly oxidized methionines. B-rhIFNalpha2b was largely unfolded and heavily aggregated. Nontreated (N) rhIFNalpha2b was immunogenic in the wild-type mice but not in the transgenic mice, showing that the latter were immune tolerant for rhIFNalpha2b. The anti-rhIFNalpha2b antibody levels in the wild-type mice depended on the degradation product: M-rhIFNalpha2b > H-rhIFNalpha2b approximately N-rhIFNalpha2b >> B-rhIFNalpha2b; G-rhIFNalpha2b did not induce anti-rhIFNalpha2b antibodies. In the transgenic mice, only M-rhIFNalpha2b could break the immune tolerance. CONCLUSIONS: RhIFNalpha2b immunogenicity is related to its structural integrity. Moreover, the immunogenicity of aggregated rhIFNalpha2b depends on the structure and orientation of the constituent protein molecules and/or on the aggregate size.
Authors: J L Ottesen; P Nilsson; J Jami; D Weilguny; M Dührkop; D Bucchini; S Havelund; J M Fogh Journal: Diabetologia Date: 1994-12 Impact factor: 10.122
Authors: T Fehr; M F Bachmann; E Bucher; U Kalinke; F E Di Padova; A B Lang; H Hengartner; R M Zinkernagel Journal: J Exp Med Date: 1997-05-19 Impact factor: 14.307
Authors: Maryam Ahmadi; Christine J Bryson; Edward A Cloake; Katie Welch; Vasco Filipe; Stefan Romeijn; Andrea Hawe; Wim Jiskoot; Matthew P Baker; Mark H Fogg Journal: Pharm Res Date: 2015-04 Impact factor: 4.200
Authors: Angelika J Freitag; Maliheh Shomali; Stylianos Michalakis; Martin Biel; Michael Siedler; Zehra Kaymakcalan; John F Carpenter; Theodore W Randolph; Gerhard Winter; Julia Engert Journal: Pharm Res Date: 2014-08-15 Impact factor: 4.200
Authors: Srivalli Telikepalli; Heather E Shinogle; Prem S Thapa; Jae Hyun Kim; Meghana Deshpande; Vibha Jawa; C Russell Middaugh; Linda O Narhi; Marisa K Joubert; David B Volkin Journal: J Pharm Sci Date: 2015-03-05 Impact factor: 3.534
Authors: Khosrow Khodabandehlou; Amar S Kumbhar; Sohrab Habibi; Ashish A Pandya; J Christopher Luft; Saad A Khan; Joseph M DeSimone Journal: ACS Appl Mater Interfaces Date: 2015-03-05 Impact factor: 9.229
Authors: Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot Journal: Mol Pharm Date: 2013-05-02 Impact factor: 4.939
Authors: John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter; Ying-Xin Fan; Susan Kirshner; Daniela Verthelyi; Steven Kozlowski; Kathleen A Clouse; Patrick G Swann; Amy Rosenberg; Barry Cherney Journal: J Pharm Sci Date: 2009-04 Impact factor: 3.534